Clinical Trial: The EMPA-FIT Study

U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846411) titled 'The EMPA-FIT Study' on Feb. 20.

Brief Summary: This multicenter, open-label, prospective study randomized 46 drug-naive adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.

Study Start Date: Jan. 01, 2024

Study Type: INTERVENTIONAL

Condition: Diabetes Diabetes Mellitus, Type II

Intervention: DRUG: Empagliflozin 10 mg

The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.

DRUG: Metformin

The primary objective was to evaluate the effic...